Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

Over the years, I’ve had the privilege of working alongside some extraordinary leaders. When I reflect on those who have left the most lasting impact on me, I often describe them as having what I call ...

Early-stage companies thrive on being nimble and running rather than walking. In times when funding is flowing and the IPO market is open, early partnering may be viewed with some skepticism out of ...

Delivering reliable, high-quality software at speed requires more than fast coding—it demands a smarter approach to testing. That’s where the Shift-Left methodology comes in. By moving testing ...

France's Early Access Program (EAP) is a critical pathway for patients with severe or rare conditions to swiftly access innovative therapies, having granted over 120,000 patients early access since ...

The patient perspective is now a critical component in assessing the value of new therapies, moving beyond traditional reliance on strictly clinical endpoints like mortality and tumor shrinkage.

The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech ...

On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and ...